Posted by Michael Wonder on 27 Feb 2023
Glaukos submits new drug application to US FDA for iDose TR
27 February 2023 - Glaukos today announced the submission of its new drug application to the US FDA for iDose® TR.
iDose TR is a micro-invasive intra-ocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.
